// you're reading...

News

Pilot commercial productions of the monoclonal autoantibody IC2

R&D collaboration with The Danish State Serum Institute, Copenhagen, Denmark  concerning pilot production of the beta-cell specific monoclonal autoantibody IC2. The pilot preparation has been tested in Paris and Copenhagen. The unique specificity of IC2 against the plasma membrane of insulin-producing beta-cells was confirmed.

Possible outsourcing contract with the biotech company Exbio, Prague, for a extensice large scale production of IC2 will be considered after a new  pilot productions, antibody fragmentation, additional functional testing and eventual DNA-cloning of the specificity.

Immunosigns own in vitro production scheme uses INTEGRA double chamber cell culture flask, purification of rat IgM by monoclonal MARK-1 affinity chromatography, eventual antibody fragmentation, and appropriate quality and functional specificity control by flow cytometry.

Welcome to ImmunoSigns

ImmunoSigns is a Biotech company founded in 1996. We offer you help in project management and R&D activities within biotechnology and immunodetection.

The core competance of ImmunoSigns is development and production of polyclonal and monoclonal antibodies and design and production of novel immunoassays and diagnostic kits, especially within the clinical area of diabetes and obesity.

Shopping Cart